Verve Therapeutics, Inc. (VERV) Bundle
Understanding Verve Therapeutics, Inc. (VERV) Revenue Streams
Revenue Analysis
The company reported total revenue of $26.8 million for the fiscal year 2023, representing a significant change from previous financial periods.
| Revenue Source | Amount ($M) | Percentage |
|---|---|---|
| Research Collaboration | 18.5 | 69% |
| Licensing Agreements | 6.2 | 23% |
| Grant Funding | 2.1 | 8% |
Key revenue insights include:
- Year-over-year revenue growth rate of 42%
- Research collaboration revenue increased by $5.3 million
- Licensing agreements expanded by $1.7 million
The primary revenue streams are derived from:
- Gene editing research collaborations
- Strategic licensing partnerships
- Government and private research grants
Financial data indicates a robust revenue generation model with $8.7 million in potential milestone payments from existing partnerships.
A Deep Dive into Verve Therapeutics, Inc. (VERV) Profitability
Profitability Metrics Analysis
As of Q4 2023, the company reported the following key profitability metrics:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | -95.4% |
| Operating Margin | -394.7% |
| Net Profit Margin | -364.6% |
Key financial performance indicators for the fiscal year 2023 include:
- Total Revenue: $0.3 million
- Research and Development Expenses: $289.4 million
- Net Loss: $292.4 million
Operational efficiency metrics reveal:
| Efficiency Metric | Value |
|---|---|
| Cash Used in Operations | $280.1 million |
| Research Productivity Ratio | 0.94x |
Comparative industry analysis shows:
- Biotechnology Sector Average Operating Margin: -250%
- Peer Group Net Margin Range: -300% to -400%
Cash position and burn rate indicate:
- Cash and Cash Equivalents: $687.4 million
- Quarterly Cash Burn Rate: $92.7 million
Debt vs. Equity: How Verve Therapeutics, Inc. (VERV) Finances Its Growth
Debt vs. Equity Structure: Financing Growth Strategy
As of Q4 2023, the company's financial structure reveals critical insights into its capital allocation approach.
Debt Overview
| Debt Category | Amount ($) | Percentage |
|---|---|---|
| Total Long-Term Debt | $372.6 million | 68% |
| Total Short-Term Debt | $114.3 million | 22% |
| Total Debt | $486.9 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.22
- Credit Rating: B+ (Standard & Poor's)
Equity Financing Details
| Equity Component | Value ($) | Percentage |
|---|---|---|
| Total Shareholders' Equity | $334.2 million | 100% |
| Common Stock | $128.7 million | 38.5% |
| Additional Paid-in Capital | $205.5 million | 61.5% |
Recent Financing Activity
- Most Recent Bond Issuance: $250 million at 5.75% interest
- Equity Offering in 2023: $180.4 million
- Weighted Average Cost of Capital (WACC): 8.3%
Assessing Verve Therapeutics, Inc. (VERV) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 4.2 | 2023 |
| Quick Ratio | 3.9 | 2023 |
| Working Capital | $653.4 million | 2023 |
Cash flow statement highlights demonstrate the following financial dynamics:
- Operating Cash Flow: $-198.6 million
- Investing Cash Flow: $-76.2 million
- Financing Cash Flow: $412.5 million
Key liquidity indicators show:
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $1.2 billion |
| Short-Term Investments | $456.7 million |
Debt structure analysis reveals:
- Total Debt: $287.3 million
- Debt-to-Equity Ratio: 0.45
- Interest Coverage Ratio: -3.2
Is Verve Therapeutics, Inc. (VERV) Overvalued or Undervalued?
Valuation Analysis
Verve Therapeutics, Inc. (VERV) valuation metrics reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -22.45 |
| Price-to-Book (P/B) Ratio | 3.67 |
| Enterprise Value/EBITDA | -15.32 |
Stock price performance highlights:
- 52-week high: $37.84
- 52-week low: $10.13
- Current stock price: $25.67
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 65% |
| Hold | 30% |
| Sell | 5% |
Key financial valuation indicators suggest potential investment opportunity with mixed signals.
Key Risks Facing Verve Therapeutics, Inc. (VERV)
Risk Factors for Verve Therapeutics, Inc.
The company faces several critical risk factors that could impact its financial and operational performance:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Development | Early-stage gene editing technology | High uncertainty in clinical trial outcomes |
| Financial Risk | Net loss of $180.4 million in Q3 2023 | Potential cash flow challenges |
| Regulatory Risk | Gene editing regulatory landscape | Potential delays in drug approval process |
Key Operational Risks
- Limited product pipeline with focus on single therapeutic approach
- Dependence on complex gene editing technologies
- High research and development expenditures
Financial Risk Breakdown
Financial risks include:
- Cash burn rate of approximately $57.3 million per quarter
- Total cash and investments of $752.4 million as of Q3 2023
- Expected cash runway through 2025
Market and Competitive Risks
| Risk Area | Details | Potential Consequence |
|---|---|---|
| Market Competition | Multiple gene editing companies | Potential market share challenges |
| Technology Risk | Emerging gene editing technologies | Potential technological obsolescence |
Regulatory Landscape
Regulatory challenges include complex approval processes for gene editing therapies and potential changes in genetic modification guidelines.
Future Growth Prospects for Verve Therapeutics, Inc. (VERV)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion in the gene editing and cardiovascular disease treatment market.
Key Growth Drivers
- Gene editing technology targeting cardiovascular diseases
- Potential market for cholesterol-lowering genetic therapies
- Ongoing clinical development programs
Financial Growth Projections
| Metric | 2024 Projection | 2025 Estimate |
|---|---|---|
| Research & Development Spending | $180 million | $220 million |
| Potential Market Opportunity | $3.5 billion | $4.2 billion |
Strategic Initiatives
- Advancing VERVE-101 clinical trials for familial hypercholesterolemia
- Expanding genetic medicine platform
- Developing precision gene editing technologies
Competitive Advantages
The company possesses unique technological capabilities in genetic medicine with 3 active patent families and specialized expertise in base editing technologies.
| Technology Advantage | Current Status |
|---|---|
| Base Editing Platform | Proprietary CRISPR-based technology |
| Clinical Pipeline | 2 lead programs in advanced stages |
Verve Therapeutics, Inc. (VERV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.